Home » The News » Page 38

Category Archives: The News

Quick info on new developments

Does The Taxpayer Get Rewarded For Funding Such Studies?

Posted on by — No Comments ↓

Cabotegravir (S-1265744) is an integrase inhibitor similar to dolutegravir.  When formulated as a long-acting drug using crystalline nanoparticle technology it is called GSK’744 LAP.  When injected intramuscularly, ‘744 LAP it has a half-life of >1 month which makes it ideally suited for PrEP of HIV for high-risk patients who nowadays are Continue reading Does The Taxpayer Get Rewarded For Funding Such Studies?→

Brilacidin – QIDP Drug At a Critical Juncture

Posted on by — 3 Comments ↓

At around this time (July 2015), Cellceutix is expected to hammer out a Phase 3 program for brilacidin, its defensin-mimetic and host-defense protein (HDP) mimic structurally similar to magainin, with FDA. Brilacidin is certainly an interesting novel compound, coming from a new class, with a unique mode of action.  It has Continue reading Brilacidin – QIDP Drug At a Critical Juncture→

Plazomicin – A Quick Take On A Complex Drug With A Complex Development Path

Posted on by — No Comments ↓

Whenever a new drug is in late stage development, its prospects become the focus of intense scrutiny. Plazomicin (ACHN-490), like any Phase 3 drug should be evaluated along the following dimensions: Differentiation: within its class & compared to competitors: Does it have a unique clearly definable profile? Addressing an unmet need: Continue reading Plazomicin – A Quick Take On A Complex Drug With A Complex Development Path→